权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Fate and efficacy of targeted therapies for metastatic tumors

转移性肿瘤靶向治疗的命运和疗效

基本信息

批准号：
9428627
负责人：
Khalid A Shah
金额：
$ 38.87万
依托单位：
BRIGHAM AND WOMEN'S HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-07-01 至 2021-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9428627
关键词：
Adopted Agonist Apoptosis Apoptotic Arteries Blood - brain barrier anatomy Blood Vessels Boston Brain Brain Neoplasms Breast Cancer Patient Cell Death Cell Proliferation Cell Therapy Cessation of life Clinic Clinical Collaborations Cranial Irradiation Data Deposition Development Diagnosis Engineering Epidermal Growth Factor Receptor Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Epigenetic Process Epithelial Estrogen Receptors Failure Genetic Goals Histone Deacetylase Histone Deacetylase Inhibitor Home environment Homing Human Human Engineering Image Impaired cognition Incidence Induction of Apoptosis Injectable Injection of therapeutic agent Intracarotid Intracranial Neoplasms Mammary Neoplasms Mediating Mesenchymal Mesenchymal Stem Cells Metastatic breast cancer Metastatic malignant neoplasm to brain Metastatic to Modality Modeling Molecular Mus Neoplasm Metastasis Operative Surgical Procedures Optics Pathology Pathway interactions Patients Permeability Positron-Emission Tomography Primary Neoplasm Progesterone Receptors Publishing Radiation therapy Residual Tumors Role Savings Signal Pathway Signal Transduction Site Stem cells Systemic Therapy TNFRSF10A gene TNFRSF10B gene TNFSF10 gene Testing Therapeutic Time Translating Treatment Efficacy Tumor-Derived Variant base cancer cell clinically translatable design efficacy testing imaging biomarker improved in vitro testing in vivo in vivo imaging killings malignant breast neoplasm mouse model nanobodies neoplastic cell nerve stem cell novel optical imaging prevent radiotracer receptor relating to nervous system response screening success targeted agent targeted treatment triple-negative invasive breast carcinoma tumor tumor growth tumor progression

项目摘要

ABSTRACT Patients with advanced breast cancer have a high propensity to metastasize to the brain with human epidermal growth factor receptor (EGFR) positive and triple-negative breast cancer (TNBC; estrogen receptor, progesterone receptor and Her2 negative) subtypes showing the highest incidence of brain metastases. Most patients have multiple metastatic lesions at the time of diagnosis making surgery an inadequate therapeutic option on its own. Furthermore, impaired cognitive decline induced by whole-brain radiation therapy (WBRT) and the tight blood brain barrier (BBB) preventing the brain permeability of systemic therapies in the brain pose challenges for the success of existing therapies and result in failure to improve overall patient survival. To effectively treat multiple highly aggressive breast metastatic foci in the brain, there is an urgent need to develop tumor specific multi-targeting agents that simultaneously target multiple aberrant signaling pathways in TNBC and utilize delivery vehicles which specifically seek metastatic foci in the brain. In our previously published and preliminary studies, we have 1) extensively demonstrated that engineered human and mouse neural stem cells (NSC) and mesenchymal stem cells (MSC) home extensively to primary and metastatic tumors in the brain and provide on-site means to deliver novel tumor specific agents; and 2) engineered EGFR-specific nanobodies (ENb) and their pro-apoptotic variant, bi- functional ENb-TRAIL and shown its potential to target both cell proliferation and death pathways in a mechanism based manner in broad spectrum of tumor cells. The long term goal of this proposal is to test the mechanism based therapeutic efficacy of systemically delivered NSC-ENb-TRAIL in TNBC derived mouse models of breast to brain metastasis that mimic the clinical scenario of breast metastatic tumor growth and progression. We will initially screen established and patient derived TNBC lines for their response to EGFR and DR4/5 targeted therapies and assess their propensity to metastasize to brain. The mechanism based response of TNBC to NSC-ENb-TRAIL and the fate and therapeutic efficacy of NSC-ENb-TRAIL in brain metastasis mouse models generated from brain seeking patient derived TNBC lines will be assessed. We hypothesize that simultaneous targeting of EGFR and DR4/5 will significantly influence epithelial-mesenchymal transition (EMT) and tumor growth and progression. Based on our exciting preliminary data on the combined use BBB permeable histone deacetylase inhibitor (HDACi), CN147 and ENb-TRAIL and the previous findings that concomitant use of HDACi with DR4/5 agonists and EGFR inhibitors, the combined therapeutic efficacy of NSC-ENb-TRAIL and CN147 will be assessed. We hypothesize that ENb- TRAIL and HDACi will have therapeutic efficacy in metastatic TNBC with a broader range of genetic backgrounds and with varying sensitivity to ENb-TRAIL in vivo. The proposed studies in this application are likely to unravel the mechanism-based, targeted stem cell mediated therapies for metastatic breast tumors. We envision designing a strategy in which NSC-ENb-TRAIL will be injected intra-arterially to target the metastatic tumor deposits in the brain of metastatic breast cancer patients. This will have a major impact in saving the lives of many cancer patients.

摘要